Intrathecal midazolam binds with gamma aminobutyric acid-A receptors in the spinal cord leading to an analgesic effect. Clinical studies suggested that intrathecal midazolam may also reduce nausea and vomiting when used as an adjunct to other spinal medications. However, the potential neurotoxic effect of intrathecal midazolam remains a concern. This meta-analysis aims to evaluate the effectiveness and side-effects of intrathecal midazolam in the perioperative and peripartum settings. Thirteen randomised controlled studies from MEDLINE (from 1966 to July 1 2007), EMBASE and Cochrane Controlled Trials Register databases, involving a total of 672 patients, were considered. Volunteer, animal and chronic pain studies were excluded. Adding intrathecal midazolam to other spinal medications reduced the incidence of nausea and vomiting (odds ratio 0.50, 95% confidence interval [CI] 0.27 to 0.90, P=0.02; I 2 =4%) and delayed the time to request for rescue analgesia 95% CI: 76.1 to 121.4, P <0.00001; I 2 =98.5%). Intrathecal midazolam did not affect the duration of motor blockade (weighted-mean-difference =25.1 min, 95% P=0.13, I 2 =94.8%). The incidence of neurological symptoms after intrathecal midazolam was uncommon (1.8%) and did not differ from placebo (odds ratio 1.20, 95% CI 0.22 to 6.68, P=0.84). Based on the limited data available, intrathecal midazolam appears to improve perioperative analgesia and reduce nausea and vomiting during caesarean delivery. A multicentre registry or large randomised controlled study with a prolonged follow-up period would be useful to confirm the clinical safety of intrathecal midazolam.
Gamma aminobutyric acid (GABA) receptors in the spinal cord play an important role in antinociception. Intrathecal midazolam binds to the gamma aminobutyric acid-A (GABA A ) receptors in the spinal cord and can reduce chronic back pain and spasticity 1, 2 . Several clinical studies showed that the systemic side-effects of intrathecal midazolam are uncommon and that adding intrathecal midazolam to other spinal medications may reduce the risk of perioperative nausea and vomiting 3 . However, a potential neurotoxic effect of intrathecal midazolam has been reported in rat and rabbit models 4, 5 . The clinical relevance of these small animal studies has been challenged because a large dose of intrathecal midazolam was administrated into a small intrathecal space, resulting in a very high concentration of midazolam around the spinal cord. Furthermore, whether preservative-free intrathecal midazolam was used in these small animal studies was also not clear 6 . Subsequently, a neurotoxic effect was not observed after a prolonged infusion (up to 43 days) of preservative-free intrathecal midazolam in a sheep and pig model 6 . An observational study involving 547 patients who had received intrathecal midazolam also did not demonstrate an increased risk of neurological symptoms after one month of follow-up following intrathecal midazolam administration 7 .
Because of this uncertainty about the risks and anaesthesia practice in many institutions remains uncommon. In this study we aimed to review the existing literature so as to evaluate and quantify midazolam, when used as an adjunct to other intrathecal medications in spinal anaesthesia in the acute pain setting.
MATERIALS AND METHODS
Two researchers searched the MEDLINE (1966 to July 1, 2007) , EMBASE and Cochrane Controlled Trials Register (2007 issue 3) databases independently. During the electronic database search, the following exploded MeSH terms were used: "midazolam" and "intrathecal", "subarachnoid" or "spinal". The reference lists of related reviews relevant trials. Finally, the web sites of International Network of Agencies of Health Technology Assessment and International Society of Technology Assessment in Health Care were searched.
Only randomised controlled clinical trials or quasi-randomised controlled clinical trials in the peri-operative settings were included in this meta-analysis. Studies with more than one active component were included if both intervention and control groups were exposed to the other active spinal medications. Clinical trials that compared intrathecal midazolam with another active spinal medication, such as intrathecal fentanyl, but without a separate placebo control group in the same trial, were excluded. There were no language restrictions applied, but chronic pain, animal and volunteer studies were excluded.
Two independent reviewers examined the full text inclusion criteria. They examined and recorded the trial characteristics and outcomes independently, using a pre-designed article abstraction form. This abstraction form was used to record information regarding the quality of the trial such as allocation concealment, randomisation method, blinding of treatment and inclusion and exclusion criteria. The grading of allocation concealment was based on the Cochrane approach, that is-adequate, uncertain or clearly inadequate. There were no disagreements between the two independent reviewers for the data extracted. Data were checked and entered into the Review Manager (version 4.2.6 for Windows. Oxford, England: The Cochrane Collaboration, 2003) database for further analysis.
Statistical analysis
The proportion of patients with nausea and vomiting (with or without anti-emetic treatment) and the time to request for rescue analgesia were chosen as the main outcomes. There were no missing data for these two main outcomes in the trials included. The other outcomes assessed included visual analogue scale (VAS) pain scores between two and four hours after administration of intrathecal midazolam; a change in respiratory status or development of respiratory depression requiring mechanical ventilation; an increase in oxygen of motor blockade (which may suggest subtle after the operative procedure.
The differences in categorical outcomes between intrathecal midazolam and placebo were reported (CI), using a random effect model. The differences in continuous outcomes were reported as weightedmean-difference (WMD) with 95% CI, using a random effect model. If only the median and range were reported in the original studies but the data were nearly normally distributed, the median would be assigned as the mean and the standard deviation was estimated by (0.95×range)/4. The extent of inconsistency or heterogeneity between trials was assessed using I 2 statistics 8 . Multiple parallel comparisons in the same study were labelled with the same study identity name followed by either "a" or "b" in the forest plots. Sensitivity analysis was conducted by excluding two studies that used slightly different concurrent treatments in the intrathecal midazolam and control groups 3, 9 . Publication bias was assessed by funnel plot, using the proportion of patients with nausea and vomiting as an end-point. All tests were two-tailed and a P value less than 0.05
RESULTS
were subject to meta-analysis ( Figure 1) 3, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . There was agreement on inclusion assessment between the two reviewers. The 13 studies included involved data from 672 patients from seven countries and all were published in English (Table 1) . One studies involved obstetric patients and seven studies involved general surgical patients. Two studies assessed two doses of intrathecal midazolam (1 and 2 mg) in different subgroups 15, 18 , two studies used 1 mg of intrathecal midazolam 17, 19 , eight studies used 2 mg of intrathecal midazolam and one study used 2.5 mg intrathecal midazolam 20 . Eleven studies compared intrathecal midazolam with an intrathecal placebo with the same concurrent spinal and systemic medications. One study compared intrathecal midazolam plus intrathecal bupivacaine with intravenous metoclopramide plus intrathecal bupivacaine 3 . One study compared intrathecal midazolam plus a lower dose of intrathecal bupivacaine (1.0 ml 0.5% hyperbaric bupivacaine) with a slightly higher dose of intrathecal bupivacaine (1.5 ml 0.5% hyperbaric bupivacaine) plus 0.5 ml intrathecal normal saline 9 . These latter two studies were excluded in the sensitivity analysis. Double-blinding was used in eight studies but adequate allocation concealment was clearly described in only four studies 10, 11, 16, 17 .
Adding intrathecal midazolam to other spinal medications reduced the incidence of nausea and vomiting (OR 0.50, 95% CI: 0.27 to 0.90, P=0.02; I 2 =4%) ( Figure 2 ), delayed the time to request for rescue analgesia (WMD=98.7 min, 95% CI: 76.1 to 121.4, P <0.00001; I 2 =98.5%) and improved the VAS pain scores between two and four hours (WMD=-0.98, 95% CI: -1.6 to -0.4, P=0.001; (Figures 3 and 4) . Intrathecal midazolam did not affect the duration of motor blockade (WMD=25.1 min, 95% CI: -7.6 to 57.8, P=0.13, I 2 =94.8%) ( Figure 5 ). The incidence of neurological symptoms after intrathecal midazolam was uncommon (1.8%) and did not differ from placebo (OR 1.20, 95% CI: 0.22 to 6.68, P=0.84) [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Respiratory depression requiring an increase in oxygen therapy, mechanical ventilation or among the 192 patients in eight studies randomised to intrathecal midazolam 3, 10, [12] [13] [14] 16, 17, 20 .
Number of trials with information on the following outcomes: Nausea and vomiting (n=11) Neurological symptoms or deficits (n=10) Respiratory depression (n=7) Duration of analgesia before rescue analgesia (n=10) Visual analogue scale (VAS) pain score between 2 and 4 hours after intrathecal idazolam administration ( pharmacoeconomic analysis was performed in any of the included studies. Sensitivity analyses, by excluding the two studies that used slightly different concurrent treatments, did not change the effect of evidence suggests that intrathecal midazolam may be particularly effective when spinal anaesthesia is used for caesarean delivery. Despite the potential analgesic effect of intrathecal midazolam having been described for over 20 years, its clinical application in acute pain setting has been limited by the concern about its potential neurotoxicity 4, 5, 22 . The results of a recent clinical cohort study and a large animal study are more reassuring 6, 7 . This meta-analysis provides additional support, albeit limited, that a small diluted dose (1 to 2.5 mg, <1 mg/ml concentration) of preservative-free intrathecal midazolam appears to have few systemic side-effects and is free of short-term neurotoxicity. Nevertheless, midazolam is a weak water-soluble base and its solubility in water is pH dependent, so as such, mixing it with other spinal medications could potentially affect its solubility 22 . Therefore, the clinical compatibility of intrathecal midazolam with other spinal medications must be carefully considered and should have been formally tested before combining for spinal anaesthesia in clinical anaesthesia practice or trials 22 . A large multicentre registry of intrathecal midazolam with long-term follow-up of more than six weeks would human.
This meta-analysis has some limitations. First, as with any overview, meta-analysis is prone to bias. In order to avoid selection bias, we have searched studies from three databases with no language 
DISCUSSION
that intrathecal m effect and may reduce the risk of postoperative nausea and vomiting. Side-effects such as respiratory depression, prolonged motor blockade and neurotoxicity appear to be rare and were not Many spinal medications have been used to improve analgesia with variable results. Studies have shown that intrathecal midazolam, either alone or when combined with other spinal medication, can improve analgesia 21 . Our results suggest that intrathecal midazolam can be useful as an adjunct to other spinal medications for perioperative analgesia. Furthermore, intrathecal midazolam may also reduce the risk of nausea and vomiting by up to 50% when added to other active spinal improvement of acute somatic pain. The exact mechanism through which intrathecal midazolam can reduce nausea and vomiting remains uncertain. One study suggested that intrathecal midazolam may reduce visceral pain that initiates emesis 3 .
had also been demonstrated in animal models 22 . Our results further support this hypothesis because the anti-emetic effect of intrathecal midazolam appeared most prominent in the two studies that evaluated its analgesic effect for caesarean delivery under spinal anaesthesia 12, 15 . Therefore, the existing restrictions. Although the funnel plot ( Figure 6 ) did not suggest the presence of publication bias, many of the trials included were small and were published by the same group of investigators. Furthermore, the quality and sample size of the included studies was not satisfactory. For instance, only four studies had adequate allocation concealment and three studies followed up their patients for longer than four weeks after hospital discharge 14, 16, 17 . Serious sideanaesthesia are likely to be rare and may develop only after hospital discharge. Thus, the small sample size and the short duration of follow-up in most of heterogeneity was observed in the effects of intrathecal midazolam on the duration of analgesia, motor blockade and VAS pain scores between two and four hours after its administration. The heterogeneity in these outcomes was most likely due to different patient cohorts and also different types and doses of concurrent spinal medications. Therefore, the overall pooled estimates of these outcomes have to be interpreted with caution and cannot be generalised to other patient cohorts. Third, the control group of two studies was used twice for data analysis in the forest plots 15, 18 . If we use Bonferroni correction for the multiple comparisons, the overall reduction in risk of nausea and vomiting after intrathecal midazolam becomes P=0.06). Finally, no studies have reported on the pharmacoeconomic midazolam. Future studies of intrathecal midazolam should include a formal cost-effective and pharmacoeconomic analysis.
In summary, based on the limited data available, adding intrathecal midazolam to other spinal medications improves perioperative or peripartum analgesia and reduces nausea and vomiting during caesarean delivery. A small diluted dose of intrathecal midazolam (1 to 2.5 mg) does not appear to increase the duration of motor blockade, the risk of respiratory depression or of short-term study or multicentre registry with a prolonged follow-up period beyond six weeks would be useful midazolam.
